case study

Pharmaceutical Development and Regulatory Submission

A global manufacturer of pharmaceuticals was facing potential expiration of a substantial quantity of API when their API manufacturer suddenly exited the relationship. RCA was asked to assist with remediating the situation.

About RCA
Regulatory Compliance Associates® Inc. (RCA) provides worldwide services to the pharmaceutical, biologic, sterile compounding, biotechnology, and medical device industries for resolution of compliance and regulatory challenges.

Please complete the form to access the case study.

*=Required

Pharmaceutical Development and Regulatory Submission

Background

A global manufacturer of pharmaceuticals was facing potential expiration of a substantial quantity of API when their API manufacturer suddenly exited the relationship. The API was controlled and maintained in storage, but had no FDA approval or updated FDA Regulatory Submission.

Additionally, there was question about the supplier’s Drug Master File (DMF), the development data, and the process for setting up a new supplier.

RCA saved the API from expiration, handled the submission, and passed without a single deficiency.

Solution

Regulatory Compliance Associates® Inc. was asked to remedy the situation. RCA retested the API, ensuring the controlled storage had indeed maintained the API with no degradation. Further, RCA qualified a new supplier, solving manufacturing issues by bringing analytical chemists and development scientists. The scientists addressed particle size and crystal drying issues that emerged within the new supplier’s manufacturing process.

RCA also brought in a regulatory team who assessed the previous API supplier’s DMF. The team found significant API development work, stability data and enabled the pharmaceutical client to submit a CBE 30 supplement. This enabled the FDA with updated information needed approve the use of the API.

Result

Not a single deficiency was found in the Regulatory Submission. The pharmaceutical company was able to use the original API, a savings well into the 8-figure range. Additionally, RCA had organized and updated the company’s Common Technical Documents (CTD), giving them templates for the life cycle management of the drug going forward. This enabled the pharmaceutical company to avoid a large API expense, maintain a revenue stream of the product, and ensure a stable manufacturing process going forward.

Background

A global manufacturer of pharmaceuticals was facing potential expiration of a substantial quantity of API when their API manufacturer suddenly exited the relationship. The API was controlled and maintained in storage, but had no FDA approval or updated FDA Regulatory Submission.

Additionally, there was question about the supplier’s Drug Master File (DMF), the development data, and the process for setting up a new supplier.

RCA saved the API from expiration, handled the submission, and passed without a single deficiency.

Solution

Regulatory Compliance Associates® Inc. was asked to remedy the situation. RCA retested the API, ensuring the controlled storage had indeed maintained the API with no degradation. Further, RCA qualified a new supplier, solving manufacturing issues by bringing analytical chemists and development scientists. The scientists addressed particle size and crystal drying issues that emerged within the new supplier’s manufacturing process.

RCA also brought in a regulatory team who assessed the previous API supplier’s DMF. The team found significant API development work, stability data and enabled the pharmaceutical client to submit a CBE 30 supplement. This enabled the FDA with updated information needed approve the use of the API.

Result

Not a single deficiency was found in the Regulatory Submission. The pharmaceutical company was able to use the original API, a savings well into the 8-figure range. Additionally, RCA had organized and updated the company’s Common Technical Documents (CTD), giving them templates for the life cycle management of the drug going forward. This enabled the pharmaceutical company to avoid a large API expense, maintain a revenue stream of the product, and ensure a stable manufacturing process going forward.

Interested in Learning More?

Contact Us

Our website uses cookies to give you the best possible experience.

By continuing to use this site, you agree to the use of cookies.
Continue